Radiation plus drug therapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of kidney cancer called clear cell or papillary renal cell carcinoma.
- Your cancer has spread to other parts of the body, cannot be removed with surgery, or has come back after surgery.
- You are able to have a precise type of radiation (SBRT) on most of your tumors.
- You are generally in good health (able to do daily activities) and have adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Hear when a new Locally Advanced or Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.